Finance

Lists
Q3 2026 earnings • released • EPS beat +3.86% • Revenue miss -47.74%
See results
ABSI:NASDAQ
Absci Corp
$8.45
-7.50%
(-0.69) 1D
Nov 13, 4:00:01 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ABSI...
Open
$9.37
High
$9.40
Low
$8.32
Mkt. cap
1.45B
Avg. vol.
4.11M
Volume
5.49M
52-wk high
$12.54
52-wk low
$2.24
EPS
-$0.80
Beta
2.22
Shares outstanding
171.61M
No. of employees
140
Open
$9.37
High
$9.40
Low
$8.32
Mkt. cap
1.45B
Avg. vol.
4.11M
Volume
5.49M
52-wk high
$12.54
52-wk low
$2.24
EPS
-$0.80
Beta
2.22
Shares outstanding
171.61M
No. of employees
140
News stories
From web sources and news partners
About Absci Corp
CEO-
Employees140
Founded2011
HeadquartersVancouver, Washington, United States
SectorHealth Care
IndustryBiotechnology
Websiteabsci.com
Analyst ratings
Based on 9 analysts giving stock ratings to ABSI in the past 3 months
Strong buy
Buy
8
Hold
1
Sell
0
12-month forecast
Based on 9 Wall Street analysts offering 12 month price targets for ABSI in the last 3 months.
Highest
Current $8.45
$20.00 (+136.69%)
Average
$14.75 (+74.56%)
Lowest
$10.00 (+18.34%)
Analyst
Recommendation
Action
Price target
Projected
Date
Swayampakula Ramakanth
H.C. Wainwright
Buy
Maintained
$16.00
+89.3%
11/13/2026
Andrew Tsai
Jefferies
Buy
Initiated
$14.00
+65.7%
10/29/2026
Scott Schoenhaus
KeyBanc
Buy
Maintained
$20.00
+136.7%
10/16/2026
Unknown Analyst
KeyBanc
Buy
Maintained
$20.00
+136.7%
10/16/2026
Brian Cheng
J.P. Morgan
Buy
Maintained
$15.00
+77.5%
10/12/2026
Kambiz Yazdi
BTIG
Buy
Reiterated
$16.00
+89.3%
10/06/2026
Brendan Smith
TD Cowen
Buy
Maintained
-
-
09/30/2026
Rami Katkhuda
LifeSci Capital
Buy
Maintained
$16.00
+89.3%
09/24/2026
Gil Blum
Needham
Buy
Maintained
$11.00
+30.2%
09/23/2026
Sean Laaman
Morgan Stanley
Hold
Reiterated
$10.00
+18.3%
08/17/2026
Debanjana Chatterjee
JonesTrading
Buy
Maintained
$13.00
+53.8%
08/12/2026
Srikripa Devarakonda
Truist Financial
Buy
Reiterated
$17.00
+101.2%
07/02/2026
Vamil Divan
Guggenheim
Buy
Reiterated
$15.00
+77.5%
06/25/2026
Mani Foroohar
Leerink Partners
Buy
Initiated
$12.00
+42%
06/04/2026
Unknown Analyst
Guggenheim
Buy
Reiterated
$10.00
+18.3%
05/10/2026
Last report
Nov 12, 2026
Fiscal period
Q3 2026
-$0.19 / -$0.20
+3.86%beat
Revenue / Est. (USD)
304.00K / 581.70K
-47.74%miss
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
650.00K
215.00K
318.00K
304.00K
Cost of goods sold
24.65M
19.28M
22.62M
-
Cost of revenue
24.65M
19.28M
22.62M
-
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
8.62M
9.06M
9.16M
-
Operating expense
11.44M
11.79M
11.86M
-
Total operating expenses
36.09M
31.06M
34.48M
-
Operating income
-35.44M
-30.85M
-34.16M
-
Other non operating income
1.35M
1.28M
990.00K
-
EBT including unusual items
-29.72M
-29.58M
-33.17M
-
EBT excluding unusual items
-34.12M
-29.58M
-33.17M
-
Income tax expense
-162.00K
18.00K
40.00K
-
Effective tax rate
0.55%
-0.06%
-0.12%
-
Other operating expenses
-
-
-
-
Net income
-29.56M
-29.60M
-33.21M
-
Net profit margin
-4,548.00%
-13,766.98%
-10,443.40%
-10,953.95%
Earnings per share
-0.23
-0.19
-0.21
-0.19
Interest and investment income
-
-
-
-
Interest expense
-29.00K
-18.00K
-2.00K
-
Net interest expenses
-29.00K
-18.00K
-2.00K
-
Depreciation and amortization charges
2.83M
2.73M
2.70M
-
EBITDA
-32.61M
-28.12M
-31.46M
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps